Evidence map›Paper›PMID 34630050›Full record

ArticleFrontiers in systems neuroscience2021

Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer's Disease Patients.

Aylin Cimenser, Evan Hempel, Taylor Travers, Nathan Strozewski, Karen Martin, Zach Malchano, Mihály Hajós

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in systems neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05680220 (A Double-blinded, Randomized Placebo-controlled Trial of 40 Hz Light Neurostimulation Therapy for Patients With Depression), which is not on this map. Cited by 71 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 6 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05680220 narecruitingnot on this mapstarted 2023, after this paper: background citation

A Double-blinded, Randomized Placebo-controlled Trial of 40 Hz Light Neurostimulation Therapy for Patients With Depression

TypeinterventionalSponsorKlaus MartinyRan2023 to 2027Enrolled60ConditionsMajor Depressive Disorder, Treatment Resistant DepressionArmsNeurostimulation System (NSS): Active Setting, Neurostimulation System (NSS): Sham Setting
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 6 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Gamma sensory stimulation in mild Alzheimer's dementia: An open-label extension study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aylin CimenserCognito Therapeutics, Inc., Cambridge, MA, United States.
Evan HempelCognito Therapeutics, Inc., Cambridge, MA, United States.
Taylor TraversCognito Therapeutics, Inc., Cambridge, MA, United States.
Nathan StrozewskiCognito Therapeutics, Inc., Cambridge, MA, United States.
Karen MartinCognito Therapeutics, Inc., Cambridge, MA, United States.
Zach MalchanoCognito Therapeutics, Inc., Cambridge, MA, United States.
Mihály HajósCognito Therapeutics, Inc., Cambridge, MA, United States.
Yale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathological proteins contributing to Alzheimer's disease (AD) are known to disrupt normal neuronal functions in the brain, leading to unbalanced neuronal excitatory-inhibitory tone, distorted neuronal synchrony, and network oscillations. However, it has been proposed that abnormalities in neuronal activity directly contribute to the pathogenesis of the disease, and in fact it has been demonstrated that induction of synchronized 40 Hz gamma oscillation of neuronal networks by sensory stimulation reverses AD-related pathological markers in transgenic mice carrying AD-related human pathological genes. Based on these findings, the current study evaluated whether non-invasive sensory stimulation inducing cortical 40 Hz gamma oscillation is clinically beneficial for AD patients. Patients with mild to moderate AD (

Indexed as

actigraphyactivities of daily livingAlzheimer’s diseasesensory-evoked gamma oscillationsleep

Identifiers

PMID34630050
PMCPMC8500065
OpenAlexW3201878985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.